Virtual Therapeutics entered into a merger agreement on May 29, 2024, to take EndeavorRx developer, Akili, Inc. (AKLI) private, in an all-cash deal.
As per the terms outlined in the agreement, Akili shareholders will receive $0.4340 per share of common stock in cash, representing a premium of 3.83% from the stock’s last close.